Drug combination for the treatment of viral diseases

Abstract

This invention pertains to a method for treating a human with human immunodeficiency virus infection which comprises administering to the human a therapeutically effective amount of a thymidine analog, which analog acts as an inhibitor of viral reverse transcriptase necessary for viral replication of human immunodeficiency virus, and a thymidylate synthase inhibitor, or pharmaceutically acceptable salts thereof.

Description

[0001] This is a continuation application of U.S. patent application Ser. No. 08 / 929,249 filed Sep. 10, 1997 (Lyon & Lyon Docket No. 266 / 298), which is a continuation-in-part application of U.S. patent application Ser. No. 08 / 585,287 (Lyon & Lyon Docket No. 266 / 297), filed on Jan. 11, 1996, which is a continuation-in-part application of U.S. patent application Ser. No. 08 / 403,320 filed on Mar. 14, 1995 (Lyon & Lyon Docket No. 266 / 303), all entitled "New Drug Combination for the Treatment of Viral Diseases" by Strair et al, and all hereby incorporated by reference herein in its entirety, including the drawings.[0002] The present invention relates to a method for treating a human with human immunodeficiency virus infection. The method comprises administering to the human a therapeutically effective amount of a thymidine analog, which analog acts as an inhibitor of viral reverse transcriptase necessary for viral replication of human immunodeficiency virus, and a thymidylate synthase in...

AI Technical Summary

Problems solved by technology

Therefore, diversity is a major obstacle to pharmacologic or immunologic centrol of human immunodeficiency virus infection.

Unfortunately, the currently available antiretroviral agents which have undergone clinical evaluation have only limited benefit because most patients will ultimately have evidence of worsening disease and increasing viral burden.

Since clinical failure and the appearance of virus with high level resistance to AZT both occur with evidence of increasing levels of viremia and changes in viral tropism, it has been difficult to ascribe the clinical failure solely to the development of AZT resistance (2,11).

Nevertheless, it seems likely that AZT resistance ultimately contributes to the clinical failure seen in most patients receiving prolonged AZT therapy.

While the development of viral-encoded drug resistance may contribute to the limited efficacy of currently used antiretroviral agents, it cannot explain all of the in vitro and in vivo phenomena associated with viral replication in the presence of an antiretroviral agent.

However, some of the differences may be due to cellular heterogeneity in the uptake or metabolism of the antiretroviral agents, that is, each cell population may have some cells that are refractory to the antiviral effects of the drug.

Continued viral replication in cells in which AZT is an ineffective antiretroviral agent could conceivably result in the continued growth of virus that is sensitive to AZT.

Therefore, many mechanisms may contribute to the inability of an antiviral agent to completely suppress human immunodeficiency virus infection.

Results with these defective HIV indicate that early infection in the presence of AZT often results from the infection of a cell which is refractory to the antiretroviral effects of AZT.

In addition, AZT inhibition of replication-competent HIV infection is also significantly impaired in this cell line.

Some cells, however do not efficiently metabolize AZT to the triphosphate and may overproduce the natural thymidine triphosphate, which competes with the antiviral activity of AZTIP.

Studies have demonstrated that these cells contribute to the early failure of the antiviral activity of AZT.

Since DNA and RNA are essential for cell division and growth, the effect of fluorouracil may be to create a thymine deficiency which provokes unbalanced growth and death of the cell.

Therefore, methotrexate interferes with DNA synthesis, repair, and cellular replication.

Images